Group 1 - The core point of the article is that Tianyu Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1] Group 2 - The approval was granted to Zhejiang Norde Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianyu Co., Ltd. [1] - Candesartan Cilexetil Tablets are specifically used for the treatment of primary hypertension [1]

格隆汇9月4日丨天宇股份(300702.SZ)公布，公司全资子公司浙江诺得药业有限公司(简称"诺得药业")于 近日收到国家药品监督管理局核准签发的关于坎地沙坦酯片的《药品注册证书》。 坎地沙坦酯片适用于原发性高血压。根据国家药监局网站数据查询，截至公告日，该制剂除诺得药业 外，国内生产商另有天地恒一制药股份有限公司、广州白云山天心制药股份有限公司等11家企业。 ...

Group 1 - The company Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for primary hypertension, with a total R&D investment of approximately 11.4476 million yuan by Node Pharmaceutical and its subsidiaries [1] - The projected sales revenue for Candesartan Cilexetil Tablets in domestic sample hospitals and urban retail pharmacies is approximately 294 million yuan in 2024 [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1]. Company Summary - Tianyu Co., Ltd. has successfully obtained regulatory approval for Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1]. - The approval enhances the product portfolio of Zhejiang Node Pharmaceutical Co., Ltd., potentially increasing its market presence in the hypertension treatment segment [1].

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Norde Pharmaceutical Co., Ltd. has recently received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for the treatment of primary hypertension [1]

| 药品名称 | 坎地沙坦酯片 | | | | --- | --- | --- | --- | | 英文名 | Candesartan | Cilexetil | Tablets | | 剂型 | 片剂 | | | | 规格 | 4mg | | | | 是否处方药 | 是 | | | | 申请事项 | 药品注册（境内生产） | | | | 注册分类 | 化学药品 | | | | 药品批准文号 | 国药准字 | H20258176 | | | 药品批准文号有效期 | 至 2028 年 09 | 月 04 | 日 | 1、药品基本情况 证券代码：300702 证券简称：天宇股份 公告编号：2025-061 2、药物的其他情况 浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于坎地沙坦酯片的《药品注册证书》 ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-060 浙江天宇药业股份有限公司 关于召开 2025 年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）于 2025 年 8 月 23 日在巨 潮资讯网（http://www.cninfo.com.cn）上发布了《关于召开 2025 年第二次临时股 东大会的通知》（公告编号：2025-057）。现将本次会议的有关事项再次提示如 下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会。 2、股东大会的召集人：公司董事会。 公司于 2025 年 8 月 22 日召开的第五届董事会第十四次会议，审议通过了《关 于召开 2025 年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 7、会议出席对象： 1 / 7 （1）截至 2025 年 9 月 3 日下午深圳证券交易所收市时，在 ...

Suspension and Resumption of Trading - SMIC is planning to issue A-shares to acquire minority stakes in its subsidiary, SMIC North, leading to a suspension of its stock trading [1] - Huahong Semiconductor intends to issue shares and pay cash to acquire 97.5% of Huali Micro's equity and will resume trading [2] - Tailin Micro plans to acquire 100% of Panqi Micro, both companies operate in the low-power wireless IoT chip design sector, and will resume trading [2] Mergers and Acquisitions - Xingchen Technology plans to acquire 53.3087% of Furui Kun for 214 million yuan, aiming to enhance its capabilities in connectivity, audio, and low power, thereby strengthening its SoC self-developed IP platform [3] - Huijin Co. intends to cash purchase 20% of Cooper New Energy's equity, which is expected to constitute a major asset restructuring [3] Share Buybacks - Kweichow Moutai's controlling shareholder plans to increase its stake by purchasing 3 to 3.3 billion yuan worth of company shares [4] - Kaiying Network intends to repurchase shares worth 100 to 200 million yuan [4] Investment Cooperation and Operational Status - Jiayuan Technology plans to invest 500 million yuan to acquire a portion of Endatong's equity, which is related to the optical module industry [5] - Zhiyang Innovation plans to establish a wholly-owned subsidiary with an investment of 20 million yuan to promote embodied intelligence technology innovation [6] - Yunzhu Technology plans to raise no more than 876 million yuan through a private placement for the upgrade and expansion of chip insertion integrated (CMI) component projects [6] Performance Changes - Sails reported a net profit of 2.941 billion yuan for the first half of 2025, an increase of 81.03% year-on-year [8] - BYD's net profit for the first half reached 15.51 billion yuan, up 13.79% year-on-year [8] - Lanke Technology reported a net profit of 1.159 billion yuan for the first half, a significant increase of 95.41% year-on-year [8] - Yilake Co. reported a net profit of 2.515 billion yuan for the first half, up 13.69% year-on-year, with a lithium salt project expected to start trial operations by the end of September [8] - Haowei Group reported a net profit of 2.028 billion yuan for the first half, an increase of 48.34% year-on-year, and has entered NVIDIA's supply chain [9] - Tianqi Lithium reported a net profit of 84.41 million yuan for the first half, marking a return to profitability [10] - China Rare Earth reported a net profit of 162 million yuan for the first half, also returning to profitability [10] - BeiGene reported a net profit of 450 million yuan for the first half, returning to profitability [10] - Guoxuan High-Tech reported a net profit of 367 million yuan for the first half, an increase of 35.22% year-on-year, and plans to invest up to 4 billion yuan in a new lithium-ion battery manufacturing base [10] - Lingyi Technology reported a net profit of 930 million yuan for the first half, an increase of 35.94% year-on-year [10] - Shenwan Hongyuan reported a net profit of 4.284 billion yuan for the first half, an increase of 101% year-on-year [10] - Zhongtai Securities reported a net profit of 711 million yuan for the first half, an increase of 77.26% year-on-year [10] - Guotai Junan reported a net profit of 15.737 billion yuan for the first half, an increase of 213.74% year-on-year [10] - China Shipbuilding reported a net profit of 2.946 billion yuan for the first half, an increase of 108.59% year-on-year [10] - Yangtze Power reported a net profit of 13.056 billion yuan for the first half, an increase of 14.86% year-on-year [10] - TCL Technology reported a net profit of 1.883 billion yuan for the first half, an increase of 89.26% year-on-year [10] - ST Huatuo reported a net profit of 2.656 billion yuan for the first half, an increase of 129% year-on-year [10] - Wentai Technology reported a net profit of 474 million yuan for the first half, an increase of 237.36% year-on-year [10]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Node Pharmaceuticals, has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of Olmesartan Medoxomil and Hydrochlorothiazide tablets, which are primarily used for the treatment of hypertension [1] Company Summary - Tianyu Co., Ltd. is expanding its product portfolio in the pharmaceutical sector with the FDA approval of a new generic drug [1] - The approved drug is aimed at addressing the hypertension market, which is significant given the prevalence of high blood pressure in the population [1] Industry Summary - The approval of generic drugs like Olmesartan Medoxomil and Hydrochlorothiazide is indicative of the ongoing growth and competitiveness in the pharmaceutical industry, particularly in the hypertension treatment segment [1] - The FDA's approval process for generic drugs is crucial for increasing access to affordable medications in the healthcare market [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Node Pharmaceuticals, has received approval from the U.S. FDA for the abbreviated new drug application (ANDA) of Olmesartan Medoxomil and Hydrochlorothiazide tablets, marking a significant milestone for the company in entering the U.S. market [1] Group 1 - The approved drug is primarily used for the treatment of hypertension and was developed by Cosette Pharmaceuticals, Inc., which launched it in the U.S. in June 2003 [1] - Node Pharmaceuticals submitted the ANDA to the U.S. FDA in February 2020, with a total R&D investment of approximately 7.6277 million yuan to date [1] - This approval represents the first time the company's formulation products have received U.S. FDA approval, indicating a deepening of the company's overseas business layout [1]